Experienced US Pharmaceutical Executive Dr Katie MacFarlane Joins PharmAust's Board

Highlights:

- **Experienced US pharmaceutical executive, Dr Katie MacFarlane has been appointed to PharmAust's Board of Directors as a Non-Executive Director**
- **Dr MacFarlane has over 30 years of experience in the development and commercialisation of pharmaceutical products and devices**
- **Dr MacFarlane's appointment is a further step towards establishing the Company as a global leader in neurodegenerative diseases**

17 June 2024 – Melbourne Australia: PharmAust Limited (ASX: PAA & PAAOA) ("PharmAust" or "the Company") a clinical-stage biotechnology company, is pleased to announce the appointment of experienced pharmaceutical executive, Dr Katie MacFarlane as a Non-Executive Director, effective today.

Dr MacFarlane has over 30 years of experience in the development and commercialisation of pharmaceutical products and devices. She is the Founder and President of SmartPharma, a commercial and strategic consulting firm that specialises in market and product assessments, market sizing and forecasting, pre-launch preparation and launch and marketing of pharmaceutical products for biopharmaceutical companies. Katie also currently is the Head of Commercial for Arkayli Biopharma, a startup developing a treatment for a rare pediatric disease. Previously, she was Chief Commercial Officer at Agile Therapeutics, Vice President of Marketing, Sales and New Product Planning at Warner Chilcott, and Senior Director of Marketing at Parke-Davis (now Pfizer). Dr MacFarlane is a member of the Board of Directors of Mayne Pharmaceuticals, an affiliate faculty member of the Purdue University School of Pharmacy and a Founding Member and Advisor to IPhO. She previously served on the Board of Directors for RespireRx and a nonprofit, INMED Partnerships for Children. She has a Bachelor of Science and Doctor of Pharmacy from Purdue University and completed a Postdoctoral Fellowship with Rutgers University and Hoffmann-LaRoche.

Non-Executive Chairman, Mr Sergio Duchini commented:
"We're very pleased to welcome Katie to the Board of Directors. Based in the United States, Katie's wealth of experience in developing and commercialising pharmaceutical products will be invaluable in establishing PharmAust as a global leader in neurodegenerative diseases. Katie has built an impressive and extensive network of pharmaceutical contacts over the years. PharmAust looks forward to leveraging these networks and working with Katie to lift the visibility of the Company in the US."

Non-Executive Director, Dr Katie MacFarlane commented:
"I'm delighted to be joining PharmAust's Board of Directors at this pivotal time in the evolution of the Company. The Phase 1 MEND Study results with MPL are very promising. The Company has an excellent opportunity to bring to market a much-needed new treatment for MND/ALS by completing the planned adaptive Phase 2/3 STRIKE study due to commence in H2 2024. I look forward to working closely with the Board and Management team as we execute on this next phase of growth."

This announcement is authorised for release by the Board of Directors of PharmAust Limited.

For further information, please contact:

Dr Michael Thurn
Managing Director
investorenquiries@pharmaust.com

P: +61 (3) 9692 7222
W: www.pharmaust.com

Media:
Catherine Strong
Morrow Sodali
c.strong@morrowsodali.com

P: 0406 759 268

About PharmAust Limited:

PharmAust Limited is listed on the Australian Securities Exchange (ASX Code: PAA). PAA is a clinical-stage biotechnology company developing therapeutics for neurodegenerative diseases. The company is focused on repurposing monepantel (MPL) for amyotrophic lateral sclerosis (ALS). ALS is the most common form of motor neurone disease (MND) and affects both upper and lower motor neurons.

MPL is a potent and safe inhibitor of the mTOR pathway. This pathway plays a central role in the growth and proliferation of cancer cells and degenerating neurons. The mTOR pathway regulates the cellular "cleaning process", where toxic proteins are broken down into macromolecules to be reused. This autophagic process is disrupted in most neurodegenerative diseases, including ALS.

The company recently announced positive top-line results for its Phase 1 MEND study in patients with ALS. PAA is in the planning stages for a registration adaptive Phase 2/3 STRIKE clinical study and anticipates commencing enrolment in H2 CY 2024. This single pivotal study could potentially lead to accelerated approval with the US Food and Drug Administration for monepantel for the treatment of ALS in 2026.

In 2024, the Neurodegenerative Disease Market size is estimated to be worth USD 55.12 billion, with a forecast growth (CAGR) of 7.14% the market size is expected to reach USD 77.82 billion by 2029.[1]

[1] https://www.mordorintelligence.com/industry-reports/neurodegenerative-disease-market

PharmAust Investor Hub:

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning PharmAust. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

Access the investor hub by scanning the QR code or visiting: https://investorhub.pharmaust.com/